Advertisement
Advertisement
U.S. markets open in 4 hours 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Oncorus, Inc. (ONCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.2900+0.0900 (+7.50%)
At close: 04:00PM EDT
1.2900 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement

Oncorus, Inc.

50 Hampshire Street
Suite 401
Cambridge, MA 02139
United States
857 320 6400
https://www.oncorus.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees82

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell H. Finer Ph.D.Non-Exec. Chairman126.65kN/A1959
Dr. Theodore T. Ashburn M.D., Ph.D.Pres, CEO, Principal Financial Officer, Principal Accounting Officer & Director760.13kN/A1967
Mr. Stephen W. HarbinCOO & Chief of Staff815.09kN/A1959
Dr. Christophe Queva Ph.D.Chief Scientific Officer & Sr. VP of Research545.58kN/A1968
Brian SheaDirector of Legal CounselN/AN/AN/A
Dr. John Mayer Goldberg M.D.Chief Medical OfficerN/AN/A1974
Mr. John McCabe M.B.A.AdvisorN/AN/A1970
Chris GermanControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Oncorus, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement